[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-363791-105":59,"doc-detail-363791-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","precision-oncology-in-gastric-cancer-navigating-molecular-subtypes-therapeutic-targets-and-future-horizons","Precision oncology in gastric cancer - navigating molecular subtypes, therapeutic targets, and future horizons","","Gastric cancer (GC) remains a leading cause of cancer-related mortality globally, driven by substantial inter- and intra-tumoral heterogeneity that undermines effective treatment. Although conventional chemotherapy has improved outcomes, advanced disease prognosis stays poor, prompting a shift to personalized precision oncology. This review synthesizes molecular classification systems, especially TCGA subtypes, to support therapeutic stratification. It also examines targeted therapy evolution, immune checkpoint inhibition in MSI-H and EBV-positive disease, and the emerging role of liquid biopsies. Challenges in resistance and heterogeneity guide priorities for future biomarker validation and combination strategies.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/precision-oncology-in-gastric-cancer-navigating-molecular-subtypes-therapeutic-targets-and-future-horizons/363791/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/precision-oncology-in-gastric-cancer-navigating-molecular-subtypes-therapeutic-targets-and-future-horizons/363791.png","ImageObject",300,407,{"name":92,"@type":93},"Anna Hans","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-12","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":34},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"Why is precision oncology needed for gastric cancer?","Question",{"text":112,"@type":113},"Gastric cancer shows major inter- and intra-tumoral heterogeneity, and traditional one-size-fits-all chemotherapy yields limited survival for advanced disease. Precision oncology aims to use biomarker-driven strategies to improve outcomes.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"What are the key TCGA molecular subtypes discussed for therapeutic stratification?",{"text":117,"@type":113},"The review focuses on TCGA subtypes: EBV-positive, MSI-H, genomically stable (GS), and chromosomal instability (CIN), and explains how they guide treatment decisions.",{"name":119,"@type":110,"acceptedAnswer":120},"Which treatment approaches beyond chemotherapy are highlighted?",{"text":121,"@type":113},"It reviews targeted therapies such as HER2 inhibition and emerging targets like Claudin18.2 and FGFR2, as well as immune checkpoint inhibitors (PD-1/PD-L1 blockade) in MSI-H and EBV-positive contexts. It also covers liquid biopsy tools such as CTCs and ctDNA for non-invasive monitoring.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},363791,1791146113,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":34,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},5909892332657,"https://ap-avatar.wpscdn.com/davatar_994ba38a5ba835b3df7d355c54d3ed8d","Cellular Oncology (2026) 49:90  \n[https://doi.org/10.1007/s13402-026-01218-1](https://doi.org/10.1007/s13402-026-01218-1)  \nREVIEW  \nPrecision oncology in gastric cancer: navigating molecular subtypes, therapeutic targets, and future horizons  \nYanyun Hong1,2 · Xiaodong Wang2 · Hang Yu2 · Xiaosun Liu2 · Chao Tang1  \nReceived: 17 January 2026 / Accepted: 3 May 2026 © The Author(s) 2026  \nAbstract  \nGastric cancer (GC) remains a leading cause of cancer-related mortality globally and is characterized by significant interand intra-tumoral heterogeneity, which poses major challenges to effective treatment. Although traditional “one-size-fitsall” chemotherapy regimens have improved outcomes, the prognosis for advanced disease remains poor, necessitating a paradigm shift towards personalized medicine. This review provides a comprehensive synthesis of the current landscape of precision oncology in GC. We systematically analyze the clinical implications of major molecular classification systems, particularly The Cancer Genome Atlas (TCGA) subtypes (EBV-positive, MSI-H, GS, and CIN), and their role in guiding therapeutic stratification. The integration of molecular profiling has revolutionized the management of GC. We discuss the evolution of targeted therapies, ranging from established standards, like HER2 inhibition, to emerging targets, including Claudin18.2 and FGFR2, highlighting their potential of overcoming resistance mechanisms. Furthermore, we evaluate the efficacy of immune checkpoint inhibitors (PD-1/PD-L1 blockade), specifically in the context of high microsatellite instability (MSI-H) and EBV-positive subtypes, where these have demonstrated robust antitumor activity. Beyond tissue-based markers, this article also explores the expanding role of liquid biopsies, including circulating tumor cells (CTCs) and circulating tumor DNA (ctDNA), as non-invasive tools for real-time monitoring of disease progression and therapeutic response. Precision oncology represents a transformative approach in GC, moving beyond histology toa molecularly driven treatment framework. However, realizing its full potential requires addressing challenges related to tumor heterogeneity and drug resistance. Future research must focus on validating novel biomarkers and developing synergistic combination strategies to further improve patient survival.  \nKeywords Gastric cancer · Precision oncology · Molecular subtypes · Targeted therapy · Immunotherapy · Liquid biopsy  \n􀀍 Xiaosun Liu [xiaosunliu@zju.edu.cn](xiaosunliu@zju.edu.cn)  \n􀀍 Chao Tang [chtang@zju.edu.cn](chtang@zju.edu.cn)  \n1 Children’s Hospital, Zhejiang University School of Medicine, National Clinical Research Center for Children and Adolescents’Health and Diseases, No.3333, Binsheng Rd, Hangzhou 310052, China  \n2 The First Affiliated Hospital, Zhejiang University School of Medicine, No. 79 Qingchun Road, Hangzhou, Zhejiang Province 310000, China  \n1 Introduction  \nGastric cancer (GC) constitutes a substantial global health challenge, representing the fifth most common malignancy and the fourth leading cause of cancer-related mortality worldwide. The latest global cancer statistics (GLOBOCAN 2020) annually attributes over one million new cases and approximately 769,000 deaths to GC [1] . The disease burden, accounting for nearly half of the global total, is disproportionately concentrated in Eastern Asia, particularly in China, Japan, and South Korea [2]. Despite gradual incidence rate declines in some Western populations, the absolute number of cases is projected to rise due to aging populations and population growth [3] . Clinically, GC is characterized by an insidious onset and aggressive biological behavior. Approximately 60% to 80% of patients are  \ndiagnosed at a locally advanced or metastatic stage, precluding the possibility of curative surgical resection [4] . For decades, the therapeutic landscape for such patients, mostly involving palliative chemotherapy regimens based on fluoropyrim","cbCaik5CwdpAeSTa","https://ap.wps.com/l/cbCaik5CwdpAeSTa","pdf",1668697,17,"English","# Abstract\n# Keywords\n# Introduction\n## Global burden and clinical challenges\n## Inter- and intra-tumoral heterogeneity and molecular subtypes\n## TCGA and ACRG classification systems","[{\"question\":\"Why is precision oncology needed for gastric cancer?\",\"answer\":\"Gastric cancer shows major inter- and intra-tumoral heterogeneity, and traditional one-size-fits-all chemotherapy yields limited survival for advanced disease. Precision oncology aims to use biomarker-driven strategies to improve outcomes.\"},{\"question\":\"What are the key TCGA molecular subtypes discussed for therapeutic stratification?\",\"answer\":\"The review focuses on TCGA subtypes: EBV-positive, MSI-H, genomically stable (GS), and chromosomal instability (CIN), and explains how they guide treatment decisions.\"},{\"question\":\"Which treatment approaches beyond chemotherapy are highlighted?\",\"answer\":\"It reviews targeted therapies such as HER2 inhibition and emerging targets like Claudin18.2 and FGFR2, as well as immune checkpoint inhibitors (PD-1/PD-L1 blockade) in MSI-H and EBV-positive contexts. It also covers liquid biopsy tools such as CTCs and ctDNA for non-invasive monitoring.\"}]","Precision oncology in gastric cancer - navigating molecular subtypes, therapeutic targets, and future horizons | PDF",1790153178,43,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/ba43d530154dbbfb91ebadf82a4d014a.webp",983,1305,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/5b34cb9b09b0458e4c91378716b76ebf.webp",982,1304,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/00c4f4f789aad075fdefbf18447f8d4e.webp",981,1303,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/a7a0919def3c536af332ff5152b2828d.webp",980,1301]